

**Title:** Using Shared Decision Making to Enhance Provider-Patient Engagement: Application to Chronic Myelogenous Leukemia

**Dates:** November 23, 2015 – November 23, 2017

**Locations:** [http://www.mycmesite1.com/index.aspx?case\\_id=564](http://www.mycmesite1.com/index.aspx?case_id=564)

**Learning Objectives:**

IDENTIFY important factors in a patient's lifestyle and values that assist in shared decision-making.

INTEGRATE communication and shared decision-making strategies into choosing CML treatment strategies.

**Target Audience:** This web-based video case is designed medical oncologists, hematologists, hematologist/oncologists, and oncology nurses/advanced practitioners. No prerequisites required.

**Program Overview:** The advent of tyrosine kinase inhibitor therapy has transformed the once fatal chronic myelogenous leukemia (CML) into a manageable chronic malignancy, which requires long-term pharmacological disease management. But, each treatment comes with its own risks and benefits, which can substantially affect patients' quality of life beyond simply extending life. In addition, treatment options change throughout the course of CML. Shared decision-making (SDM) is a process that aims to give patients the care that they want by making informed decisions about treatment options, while clinicians also consider patient preferences and values. SDM is a 2-way discussion designed for the patient and clinician to arrive together at the best treatment plan for that patient. This web-based video activity will employ a case study scenario to show how SDM can be implemented during the course of treating patients with CML. The video activity will also offer guidance on how to implement SDM into each clinical encounter while being mindful of today's time constraints and complex medical technologies. The video features 2 experienced hematology/oncology clinicians (a physician and a nurse) as well as the executive director of a patient advocacy organization.

**Faculty:**

Javier Pinilla-Ibarz, MD, PhD  
Associate Member  
Director of Immunotherapy  
Malignant Hematology Department  
H. Lee Moffitt Cancer Center and Research Institute  
Tampa, Florida



Lisa Nodzon, PhD, ARNP, AOCNP  
Department of Malignant Hematology  
H. Lee Moffitt Cancer Center & Research Institute  
Tampa, Florida

Sarah Krug, MS  
CEO, Cancer101  
New York, New York

**Physician Continuing Medical Education:**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and ASiM. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

**Physician Credit Designation Statement:**

Clinical and Patient Educators Association designates this enduring activity for a maximum of 0.75 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure of Conflicts of Interest:**

Clinical and Patient Educators Association (CPEA) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

**Commercial Support:** This activity is supported by an independent educational grant from Bristol-Myers Squibb.

